Clinical Trial Update: Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sintilimab plus rituximab followed by R-CHOP in untreated primary mediastinal large B-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Sintilimab (sintilimab)
• Vincristine (vincristine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Primary Mediastinal Diffuse Large B-cell Lymphoma | Phase 2 | Status: RECRUITING